Patient Heterogeneity
A treatment may look weak in aggregate trials if only a subset of patients responds strongly. Identifying responsive subgroups remains an unsolved challenge in the field. Long COVID research is complicated because patients may have differe…
1 sources - 3 claims
A treatment may look weak in aggregate trials if only a subset of patients responds strongly. Identifying responsive subgroups remains an unsolved challenge in the field. Long COVID research is complicated because patients may have different combinations of underlying drivers.